Related Tags >> Darmstadt Germany Erbitux Merck Serono Mergers and Acquisitions

Merck KgAA News

Most Popular Merck KgAA Story

Threshold, Merck KGaA strike $525M licensing deal for promising cancer drug

February 3, 2012 — 6:56am ET | By John Carroll

The dealmakers at South San Francisco-based Threshold Pharmaceuticals ($THLD) have crafted a $525 million licensing pact with Merck KGaA covering its late-stage cancer drug TH-302. Threshold snagged Read more...

Merck KgAA Press Releases

Merck KGaA and Threshold Announce Global Agreement to Co-Develop and Commercialize Phase III Hypoxia-Targeted Drug TH-302
Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer
Fluxion Biosciences To Distribute Millipore PrecisION® Ion Channel Cell Lines
Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology from Merck KGaA
EMD Millipore and Parent Company Merck KGaA Send Assistance to Flood Ravaged Thailand

Latest Headlines

Threshold, Merck KGaA strike $525M licensing deal for promising cancer drug
February 3, 2012
Cancer immunotherapy partners face big test with Phase III program
January 12, 2012
UPDATED: Idera gets FDA green light for Phase II psoriasis drug test
December 2, 2011
UPDATED: Merck KGaA bolsters MS pipeline in $20M pact with Ono
October 4, 2011
Sanofi MS drug shines, biotech strategy advances
July 11, 2011
Merck KGaA nixes development of Idera Pharma cancer drug
July 8, 2011
Merck Serono shakes up its R&D structure, brings in BMS vet
July 7, 2011
FDA's safety concerns force Merck KGaA to kill cladribine MS program
June 22, 2011
Another setback for Merck KGaA as FDA spurns cladribine app
March 2, 2011
Merck KGaA boss planning a new round of smaller deals
February 22, 2011
Organon R&D hub faces shutdown as Merck fails to close a deal
February 16, 2011
Sanofi and Merck KGaA join forces on combo cancer drugs
December 17, 2010
FDA hands Merck KGaA a new delay on cladribine
November 29, 2010
Cladribine - FDA's Top Blockbuster Decisions
October 11, 2010
EU regulators rebuff Merck KGaA on MS drug
September 24, 2010
Novartis wins landmark approval for oral MS drug
September 22, 2010
Merck KGaA back on track with MS drug
July 28, 2010
Stymied in U.S., Merck KGaA wins an approval for cladribine
July 12, 2010
Merck KGaA exec to become Millipore CEO
July 9, 2010
Merck KGaA's pancreatic cancer vaccine ready for testing
July 9, 2010

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events